Agios Pharmaceuticals, Inc. recently disclosed in an 8-K filing with the U.S. Securities and Exchange Commission that David P. Schenkein, M.D., will be resigning from the company’s Board of Directors. The effective date of Schenkein’s resignation is set for February 28, 2025.
Upon his departure from the Board, Dr. Schenkein will also no longer serve as a member of the Science and Technology Committee. Despite stepping down from these positions, Schenkein will continue his involvement with Agios Pharmaceuticals as a strategic advisor to the leadership team. In this capacity, he will focus on the progression of the company’s clinical development programs.
Schenkein’s decision to resign from these positions marks a significant transition for Agios Pharmaceuticals, with his continued advisory role signaling ongoing collaboration and support within the company’s strategic initiatives.
This completes the key information provided within the 8-K submission by Agios Pharmaceuticals regarding the resignation of David P. Schenkein from the Board of Directors.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Agios Pharmaceuticals’s 8K filing here.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Further Reading
- Five stocks we like better than Agios Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 02/10 – 02/14
